Uganda Cancer Institute Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02316444
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Uganda Cancer Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

Drugs in Phase 3 Trials (1)

carvedilol (coreg) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 4)

Hepatitis B (Phase 4)

Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2